Velsipity
What Velsipity is used for
Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Velsipity
- Active substance
- etrasimod
- Disease area
- Colitis, Ulcerative
- Medicine group
- Immunosuppressants
- ATC code
- L04AE05
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2024
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Velsipity used for?
Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
What is the active substance in Velsipity?
Velsipity contains etrasimod.
Who makes Velsipity?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU